The roles of efficacy, safety, and tolerability in antipsychotic effectiveness: Practical implications of the CATIE schizophrenia trial

Journal of Clinical Psychiatry

Volumn 68, Issue SUPPL. 1, 2007, Pages 5-11

  Nasrallah, Henry A ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE; FLUPHENAZINE DECANOATE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TRIFLUOPERAZINE; ZIPRASIDONE;

AGRANULOCYTOSIS; AKATHISIA; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; MOTOR DYSFUNCTION; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION;

ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS; EVIDENCE-BASED MEDICINE; HUMANS; PATIENT COMPLIANCE; RESEARCH DESIGN; SCHIZOPHRENIA;

EID: 33846987937     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-1223
2. Nasrallah HA, Smeltzer DJ. Contemporary Diagnosis and Management of the Patient With Schizophrenia. Newtown, Pa: Handbooks in Healthcare; 2003
3. Stahl SM, Shayegan DK. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry 2003;64(suppl 19):6-12
4. Nasrallah H, Korn M. A Rational Approach to Antipsychotic Pharmacotherapy. Medscape Clinical Update-2003. Available at: http://www.medscape.com/viewprogram/2675_pnt. Accessed July 22, 2006
5. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-796
6. Stahl SM. "Hit-and-run" actions at dopamine receptors, pt 1: mechanism of action of atypical antipsychotics. J Clin Psychiatry 2001;62:670-671
7. Meltzer HY, Li Z, Kaneda Y, et al. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:1159-1172
8. Heres S, Davis J, Maino K, et al. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry 2006;163:185-194
9. Treatment for Adolescents with Depression Study (TADS) Team. The Treatment for Adolescents with Depression Study (TADS): demographic and clinical characteristics. J Am Acad Child Adolesc Psychiatry 2005;44:28-40
10. Sachs GS, Thase ME, Otto MW, et al. Rationale, design, and methods of the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Biol Psychiatry 2003;53:1028-1042
11. Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006;354:1243-1252
12. Schneider LS, Ismail MS, Dagerman K, et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer's disease trial. Schizophr Bull 2003;29:57-72
13. Insel TR. Beyond efficacy: the STAR*D trial. Am J Psychiatry 2006;163:5-7
14. March JS, Silva SG, Compton S, et al. The case for practical clinical trials in psychiatry. Am J Psychiatry 2005;162:836-846
15. Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA 2003;290:1624-1632
16. Stroup TS, McEvoy JP, Swartz MS, et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull 2003;29:15-31
17. Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006;163:611-622
18. Swartz MS, Wagner HR, Swanson JW, et al. Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study. J Nerv Ment Dis 2006;194:164-172
19. Barry KL, Fleming MF, Greenley J, et al. Assessment of alcohol and other drug disorders in the seriously mentally ill. Schizophr Bull 1995;21:313-321
20. Nasrallah HA. CATIE's surprises: in antipsychotics' square-off, were there winners or losers? Curr Psychiatry 2006;5:49-65
21. MedLine Plus Drug Information. Phenothiazines: perphenazine. Available at: http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/202457.html. Accessed Aug 5, 2006
22. Jibson M, Glick I, Tandon R. Schizophrenia and other psychotic disorders. Focus 2004;2:17-30
23. Nasrallah HA, Meyer JM, Goff DC, et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res 2006;86:15-22
24. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005;19(suppl 1):1-93
25. McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006;163:600-610
26. Chakos M, Lieberman J, Hoffman E, et al. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry 2001;158:518-526
27. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005;80:19-32
28. Keith SJ, Kane JM. Partial compliance and patient consequences in schizophrenia: our patients can do better. J Clin Psychiatry 2003;64:1308-1315
29. Torrey EF. Studies of individuals with schizophrenia never treated with antipsychotic medications: a review. Schizophr Res 2002;58:101-115
30. Chatterjee A, Chakos M, Koreen A, et al. Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients. Am J Psychiatry 1995;152:1724-1729
31. Fenton WS. Prevalence of spontaneous dyskinesia in schizophrenia. J Clin Psychiatry 2000;61(suppl 4):10-14
32. Tenback DE, van Harten PN, Slooff CJ, et al, for the SOHO Study Group. Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) study. J Clin Psychiatry 2005;66:1130-1133